anti-cd19-car cmv-specific t-lymphocytes
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 7, 2022 (NCT05432635)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06735690 | Early Phase 1 (Phase 1) | Aug 23, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT05801913 | Phase 1 | Sep 29, 2023 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT05432635 | Phase 1 | Sep 7, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 3 | 3 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1